BioAtla, Inc. Common Stock (BCAB) Stock Price

BCABStock

$1.74−91.74%52W

Market Cap$2.89M

P/E—

PEG Ratio—

Div yield—

Beta0.60

BCAB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-93.86%

Price vs S&P 500 (4W)-48.32%

VGM Score16.33

Book Value / Share (Quarterly)$0.47

P/TBV (Annual)0.42x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)100.00%

Cash Flow / Share (Quarterly)$-22.40

Price vs S&P 500 (YTD)-106.71%

Net Profit Margin (TTM)-489.20%

EPS (TTM)$-41.82

10-Day Avg Trading Volume0.19M

EPS Excl Extra (TTM)$-41.82

Revenue Growth (5Y)-17.40%

EPS (Annual)$-50.64

ROI (Annual)-489.14%

Net Profit Margin (5Y Avg)-10141.16%

Cash / Share (Quarterly)$1.18

ROA (Last FY)-431.06%

Revenue Growth TTM (YoY)-81.82%

EBITD / Share (TTM)$-40.31

ROE (5Y Avg)-157.04%

Operating Margin (TTM)-483.05%

Cash Flow / Share (Annual)$-37.99

P/B Ratio10.47x

P/B Ratio (Quarterly)37.03x

Net Income / Employee (Annual)$-1,453,800

Net Interest Coverage (TTM)-11.49x

ROA (TTM)-309.44%

EPS Incl Extra (Annual)$-50.64

Current Ratio (Annual)0.37x

Quick Ratio (Quarterly)0.09x

3-Month Avg Trading Volume0.07M

52-Week Price Return-91.74%

Revenue / Employee (TTM)$48,800

Tangible BV / Share (Quarterly)$1.98

P/S Ratio (Annual)2.86x

Asset Turnover (Annual)0.14x

52-Week High$71.50

Operating Margin (5Y Avg)-10037.90%

EPS Excl Extra (Annual)$-50.64

26-Week Price Return-81.93%

Quick Ratio (Annual)0.32x

13-Week Price Return-57.16%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)0.15x

Enterprise Value$3.76M

Revenue / Share Growth (5Y)-26.83%

Asset Turnover (TTM)0.14x

Revenue / Employee (Annual)$48,800

Pretax Margin (Annual)-2980.35%

Cash / Share (Annual)$5.61

3-Month Return Std Dev117.16%

Net Income / Employee (TTM)$-1,234,600

ROE (Last FY)-489.14%

Net Interest Coverage (Annual)-15.82x

EPS Basic Excl Extra (Annual)$-50.64

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-41.82

ROI (TTM)-357.92%

P/S Ratio (TTM)2.86x

Pretax Margin (5Y Avg)-10141.39%

Revenue / Share (Annual)$1.70

Tangible BV / Share (Annual)$3.79

Price vs S&P 500 (52W)-110.30%

Year-to-Date Return-93.89%

5-Day Price Return-47.10%

EPS Normalized (Annual)$-50.64

ROA (5Y Avg)-150.40%

Net Profit Margin (Annual)-2980.35%

Month-to-Date Return-47.26%

Cash Flow / Share (TTM)$-2.64

EBITD / Share (Annual)$-50.41

Operating Margin (Annual)-2985.55%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-157.03%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-41.82

P/TBV (Quarterly)0.80x

P/B Ratio (Annual)2.40x

Pretax Margin (TTM)-489.20%

Book Value / Share (Annual)$12.28

Price vs S&P 500 (13W)-59.12%

Beta0.60x

Revenue / Share (TTM)$1.67

ROE (TTM)-357.92%

52-Week Low$1.51

gGradeF

mGradeD

vgmGradeF

BCAB Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q3 2025	Nov 13, 2025	-$14.83	-$13.50	+8.99%(+$1.33)
Q2 2025	Aug 7, 2025	-$14.67	-$16.00	-9.09%(-$1.33)
Q1 2025	May 6, 2025	-$14.67	-$13.00	+11.36%(+$1.67)
Q4 2024	Mar 28, 2025	-$19.00	-$15.00	+21.05%(+$4.00)

BCAB Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.29

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
BCABBioAtla, Inc. Common Stock	—	F	D	$1.74
AMGNAmgen Inc	C	C	B	$432.42
GILDGilead Sciences Inc	C	B	B	$145.68
ARGXargenx SE American Depositary Shares	D	A	B	$1023.21
MRNAModerna, Inc. Common Stock	D	C	A	$137.99
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$207.88
BIIBBiogen Inc. Common Stock	C	D	B	$218.50
BNTXBioNTech SE American Depositary Share	C	C	C	$102.08
NBIXNeurocrine Biosciences Inc	C	B	C	$154.06
EXELExelixis Inc	C	B	B	$54.45
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.35
TECHBio-Techne Corp.	D	C	B	$72.35
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$351.46
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.97
RGENRepligen Corp	D	C	B	$176.27
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$118.15
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.84
QGENQIAGEN N.V.	C	C	B	$43.11
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$141.38
IBRXImmunityBio, Inc. Common Stock	F	A	B	$8.05
IMVTImmunovant, Inc. Common Stock	—	—	B	$41.20
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$57.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.34
CRSPCRISPR Therapeutics AG	D	B	C	$57.72
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.77
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$25.19
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.00
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.01
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.76
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.32
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.82
KODKodiak Sciences Inc Common Stock	—	—	B	$37.72
MESOMesoblast Limited American Depositary Shares	D	B	B	$17.44
VCELVericel Corporation	D	B	B	$40.95
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.84
ADMAADMA Biologics, Inc.	C	C	C	$9.34
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$36.62
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.77
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.83
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$123.41
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.34
ALVOAlvotech Ordinary Shares	C	D	C	$4.95
NVAXNovavax Inc	B	D	C	$9.26
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$27.44
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.70
REPLReplimune Group, Inc.	—	—	A	$15.50
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.45
VORVor Biopharma Inc. Common Stock	—	—	B	$22.65
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.70
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.82
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.93

About BioAtla, Inc. Common Stock

BioAtla Inc is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for solid tumor cancers. The company's pipeline includes multiple programs featuring designed antibodies and bispecific antibodies, with lead candidates mecbotamab vedotin, ozuriftamab vedotin, and evalstotug in development, along with a Phase 1 trial for BA3182, a bispecific antibody targeting EpCAM and CD3. Its focus on precision-engineered antibodies aims to address unmet needs in oncology with potentially improved specificity and tolerability compared to conventional approaches.